

October 4, 2022

This HEDIS^{®1} Measurement Year (MY) 2022 Public Reporting memo outlines all measures, product lines and indicators that have been approved for public reporting starting in MY 2022 and MY 2023, as well as all measures, stratifications, and product lines that will not be publicly reported for MY 2022.

If you have questions about the information included in the tables, contact us through My NCQA (<https://my.ncqa.org>).

The following measures will be publicly reported starting in MY 2022 and MY 2023:

HEDIS Measurement Year	HEDIS Measures
2022	<p>The following measures reported using Electronic Clinical Data Systems (ECDS) will be publicly reported for MY 2022 for all product lines and indicators:</p> <ul style="list-style-type: none"> • Adult Immunization Status (AIS-E). • Prenatal Depression Screening and Follow-Up (PND-E). • Postpartum Depression Screening and Follow-Up (PDS-E). • Breast Cancer Screening (BCS-E).
2023	<p>The following measures reported using ECDS will be publicly reported for MY 2023 for all product lines and indicators:</p> <ul style="list-style-type: none"> • Depression Screening and Follow-Up for Adolescents and Adults (DSF-E). • Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E). • Depression Remission or Response for Adolescents and Adults (DRR-E). • Unhealthy Alcohol Use Screening and Follow-Up (ASF-E).

The following measures, stratifications, and product lines will not be publicly reported for MY 2022.

HEDIS Measures—MY 2022
<p>The following first-year measures will not be publicly reported for MY 2022:</p> <ul style="list-style-type: none"> • Advance Care Planning (ACP). • Antibiotic Utilization for Respiratory Conditions (AXR). • Childhood Immunization Status (CIS-E). • Immunizations for Adolescents (IMA-E). • Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E).

¹HEDIS[®] is a registered trademark of the National Committee for Quality Assurance (NCQA).

HEDIS Measures—MY 2022

The race and ethnicity stratifications for the Medicare, Medicaid and commercial product lines will not be publicly reported for MY 2022 for the following measures:

- Colorectal Cancer Screening (COL and COL-E).
- Controlling High Blood Pressure (CBP).
- Hemoglobin A1c Control for Patients With Diabetes (HBD).
- Prenatal and Postpartum Care (PPC).
- Child and Adolescent Well-Care Visits (WCV).

The following product lines will not be publicly reported for the following measures:

- Colorectal Cancer Screening (COL and COL-E)—Medicaid product line.
- Use of Imaging Studies for Low Back Pain (LBP)—Medicare product line.

The Medicare Socioeconomic Status Stratifications (SES) for the following measures will not be publicly reported for MY 2022:

- Breast Cancer Screening (BCS and BCS-E).
- Colorectal Cancer Screening (COL and COL-E).
- Eye Exam for Patients With Diabetes (EED).
- Plan All-Cause Readmissions (PCR).

The following measures reported using ECDS will not be publicly reported for MY 2022:

- Colorectal Cancer Screening (COL-E).
- Follow-Up Care for Children Prescribed ADHD Medication (ADD-E).
- Depression Screening and Follow-Up for Adolescents and Adults (DSF-E).
- Utilization of the PHQ-9 to Monitor Depression Symptoms for Adolescents and Adults (DMS-E).
- Depression Remission or Response for Adolescents and Adults (DRR-E).
- Unhealthy Alcohol Use Screening and Follow-Up (ASF-E).